Hoffmann-la Roche Inc.

Bright Peak Therapeutics Ag

Black Diamond Therapeutics, Inc.

Alexander Flohr

Roland Jakob-Roetne

Claus Riemer

Roger David Norcross

Katrin Groebke Zbinden

Matthias Koerner

Jens-Uwe Peters

Bernd Kuhn

Wolfgang Wostl

Konrad H Bleicher

Alexander Alanine

Markus Rudolph

Synese Jolidon

Guido Galley

Thomas Luebbers

Karlheinz Baumann

Aubry Kern Miller

Eric Argirios Kitas

Erwin Goetschi

Christian D Lerner

Helmut Jacobsen

Luca Claudio Gobbi

Alexander Mayweg

Rosa Maria Rodriguez-Sarmiento

Daniela Alberati

Herve Schaffhauser

Ruben Alvarez Sanchez

Emmanuel Pinard

Eric Vieira

Henner Knust

Andrew William Thomas

Johannes Aebi

Luke Green

Anja Limberg

Bjoern Bartels

Lucinda Steward

Kurt Puentener

Stephan Bachmann

Shaoning Wang

Roberto Iacone

Sonia Maria Poli

Elizabeth Buck

Serena Maria Fantasia

Luca Arista

Thomas Ryckmans

Theresa Maria Ballard

Vijaya Raghavan Pattabiraman

David M Epstein

Rubén Alvarez Sánchez

Jean-Luc Moreau

Matthew O'Connor

Nicolas Zorn

Fränzi Weibel

Görkem Kurtuldu Sahin

Camille Delon

Juillerat-Jeanneret Lucienne

Golshayan Dela

Felix Gruber

George Trainor

Katrin Groebke Zbinzen

Norcross David Roger

Jean-Philippe Carralot

Giorgio Ottaviani

Jeffrey William Bode

Claudia Fetz

Eric Armentani

Régis Boehringer

Matilde Arévalo-Ruiz

Anna Haydn

The present disclosure relates to modified IL-2 polypeptides, compositions comprising modified IL-2 polypeptides, methods of making the same, and methods of using the modified IL-2 polypeptides for treatment of diseases. In one aspect, the disclosure relates to the treatment of cancer using the modified IL-2 polypeptides. In some embodiments, the disclosed IL-2 polypeptides exhibit preferential binding characteristics to IL-2 receptor &#x3b2;&#x3b3; complex (IL-2R&#x3b2;) over IL-2 receptor &#x3b1;&#x3b2;&#x3b3; complex (IL-2R&#x3b1;). In some embodiments, the molecular weight distribution of the modified IL-2 polypeptides is monodispersed.

Modified IL-2 polypeptides and uses thereof

The present disclosure relates to new compounds or pharmaceutically acceptable salts or stereoisomers thereof of formula I as inhibitors of receptor tyrosine kinases (RTK), in particular extracellular mutants of ErbB-receptors. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the treatment of cancer in mammals (e.g. humans).

Tyrosine kinase inhibitor compositions, methods of making and methods of use

The present invention provides compounds that are muscarinic M1 receptor positive allosteric modulators (PAM) and useful in the treatment of diseases, mediated by the muscarinic M1 receptor, such as Alzheimer's disease, cognitive impairment, schizophrenia, pain or sleep disorders, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances.

1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of CNS related diseases

The instant invention relates to novel conjugates of the compound of formula (I):S&#x2014;L&#x2014;A&#x2003;&#x2003;(I)or salts thereof, wherein A is a &#x3b3;-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture, pharmaceutical compositions comprising them, and their use as medicaments.

Targeted notch pathway inhibitors

The present invention relates to compounds of formula I, wherein A, B, R, R, and Z are as defined hereinbefore. 

(Hetero)aryl imidazoles/pyrazoles for treatment of neurological disorders

The present invention provides a compound of formula I which act as inhibitors of SMAC protein binding to Inhibitor of Apoptosis Proteins (IAPs), and/or inhibitors of activated caspase protein binding to IAPs (I) their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances, alone or in combination with DR5/FAP agonist antibodies. The active compound of the present invention is useful in the amelioration, treatment or control of cancer, especially solid tumors. 

Dimeric compounds

The present invention relates to compounds of formula wherein R, Y, Y, X, R and n are as defined herein.

Pyrrolopyridine or pyrazolopyridine derivatives

The present invention relates to compounds of formula (I) and its use for the treatment of neurological disorders. 

Triazolo compounds

The present invention relates to compounds of formula (I), wherein A, B, Rand Rare as defined herein before useful for the treatment of psychiatric disorders.

Imidazole derivatives

The invention relates to compounds of formula I 

Pyrrolidino heterocycles

The present invention provides compounds of formula (Ia) and (Ib) 

Triazolo compounds as PDE10 inhibitors

The invention is concerned with triazolopyridine compounds of formula (I) wherein R, Rand Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds inhibit PDE10A and can be used as medicaments.

Triazolopyridine compounds

The invention relates to a novel process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I or of a salt thereof  2-Phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives of formula I with their 1,2,4-triazole nucleus build the structural core of a great number of functionalized molecules in medicinal chemistry.

Process for the preparation of 2-phenyl-[1,2,4]triazolo[1,5-a]pyridine derivatives

The invention relates to compounds of formula wherein the substituents are as described in claim. Compounds of formula I are modulators for amyloid beta and thus, they may be useful for the treatment or prevention of a disease associated with the deposition of &#x3b2;-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

Modulators of amyloid beta

Growing community of inventors

Loerrach, Germany

Alexander Flohr